AstraZeneca's global biologics R&D arm MedImmune has entered into a new five-year scientific and technological cooperation agreement with the São Paulo Research Foundation (FAPESP) to advance research and the scientific and technological development of the Brazilian state of São Paulo.
In order to fund selected research projects over the course of the five year agreement, the organizations will each contribute about $2m.
The deal is the result of a cross-functional effort among MedImmune, AstraZeneca Brazil and the state of São Paulo.
It will focus on identifying and accessing the best science and scientists in the cardiovascular and metabolic disease areas at public and private research institutions in São Paulo.
MedImmune Cardiovascular and Metabolic Disease (CVMD) Innovative Medicines Unit head and vice-president Cristina Rondinone said: "Cardiovasular and metabolic disease is a main therapy area for MedImmune, and we are pleased to enter this exciting new research agreement with FAPESP to find and access some of the most innovative science in the São Paulo area, a region ripe in metabolic expertise and innovation.
"Partnering with academia to identify and qualify new targets and underlying biology is critical in translating discoveries to create innovative new medicines in areas of high unmet medical need."
Under the deal, the parties will discover scientific breakthroughs in basic and translational research to offer a deeper understanding of the pathophysiology of cardiovascular and metabolic diseases as well as to apply this knowledge in the development of new and differentiated medicines for patients.
The deal will see FAPESP issue a public request for proposals in the cardiovascular and metoabolic disease areas.